Flanagan, S.P. (2023). Semaglutide in Obesity (STEP-1 Trial)-2021. In: Russell, J., Skolnik, N.S. (eds) Top Articles in Primary Care. Springer, Cham. https://doi.org/10.1007/978-3-031-25620-2_44 Download citation .RIS
Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension.Diabetes Obes Metab. 2022;24(8):1553-1564.doi: 10.1111/dom.14725 Mosenzon O, Garvey WT, Hesse D, et al. Clinically relevant weight loss is ac...
Semaglutide(索马鲁肽)是一种被批准用于治疗2型糖尿病及降低心血管疾病患者心血管事件风险的胰高血糖素样肽-1(GLP-1)类似物,基于司马鲁肽治疗肥胖症(STEP)临床试验项目的结果,在美国、欧洲、英国和加拿大司马鲁肽已被批准以2.4 mg每周一次的剂量用于超重(BMI ≥ 27 kg m–2)或肥胖(BMI ≥ 30 ...
与其他GLP-1R激动剂相比,司美格鲁肽在减肥减重方面也表现出色。一项名为“Semaglutide Treatment Effect in People with Obesity”(STEP)的研究证明,与安慰剂组相比,服用司美格鲁肽的肥胖者在治疗期间取得了更显著的体重减轻。这对于多数2型糖尿病患者来说,既是治疗结果的一部分,也提供了额外的健康益处。 4. 控制...
在《新英格兰医学杂志》(NEJM)公布的 STEP 3a 期临床试验研究的结果,研究结果显示司美格鲁肽减肥效果突出,在非糖尿病的人群中进行的试验中,该项目涉及超过 4500 例无 2 型糖尿病的肥胖或超重成人患者,接受司美格鲁肽治疗的肥胖症患者在 68 周内平均体重减轻 17-18%,试验显示安全且耐受性良好[1]。 ✔ 心血...
目前,诺和诺德正在开发每周一次semaglutide 2.4mg皮下注射制剂,作为成人肥胖症的治疗方法。semaglutide是一种的胰高血糖素样肽-1(GLP-1)类似物,可通过减少饥饿感、增加饱腹感,从而帮助人们吃得更少、减少卡路里的摄入,诱导减肥。 STEP项目(...
Once-weekly semaglutide 2.4 mg improved glucose metabolism and prediabetes in adults with overweight or obesity in the STEP 1 trialSemaglutide 2.4 mg demonstrated 14.9% body weight (BW) loss in adults with overweight/obesity in STEP 1. We evaluated effects on glucose metabolism in subjects with ...
In February 2021, the researchers published findings from the STEP 1 trial inThe New England Journal of Medicineshowing that patients who injected semaglutide lost close to 15% of their body weight, on average, compared with 2.4% among patients receiving the placebo. More than one-third of parti...
The STEP 1 trial included 1,961 adults with a BMI of 30 or greater, or those with a BMI of 27 or greater with at least one weight-related comorbidity, randomized in a 2:1 fashion. All participants were free of diabetes at baseline -- although 40% had prediabetes -- and about 75%...
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. PMID: 33667417 Semaglutide lowers body weight in rodents via distributed neural pathways. PMID: 32213703 Semaglutide (...